NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
NewAmsterdam Pharma Company N.V. (NAMS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 52.20% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 52.10%, a 10.15% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 47.30%, a 14.81% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 41.20%, a 7.01% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 38.50%.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 47.70%, a 14.11% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 41.80%, a 9.71% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 38.10%, a 1.80% decline from fiscal 2022.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 38.80%, a 9.56% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 52.20% 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 52.10% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 47.70% 10-K · filed 2026-02-18 | |||
| 2025-09-30 | 47.60% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 47.50% 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 47.30% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 41.80% 10-K · filed 2026-02-18 | |||
| 2024-09-30 | 41.70% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 41.40% 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 41.20% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 38.10% 10-K · filed 2026-02-18 | |||
| 2023-09-30 | 38.30% 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 38.40% 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 38.50% 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 38.80% 10-K · filed 2025-02-26 | |||
| 2021-12-31 | 42.90% 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |